Document:

<PAGE>
                                                                   Exhibit 10.18

                                                                  EXECUTION COPY

--------------------------------------------------------------------------------

                  AMENDED AND RESTATED NOTE PURCHASE AGREEMENT

                                  BY AND AMONG

                              EPICEPT CORPORATION,
                             AS BORROWER AND ISSUER

                                       AND

                        THE PURCHASERS IDENTIFIED HEREIN

                                 August 26, 2005

--------------------------------------------------------------------------------
<PAGE>
     THIS AMENDED AND RESTATED NOTE PURCHASE AGREEMENT (this "AGREEMENT"), dated
as of August 26, 2005, is by and among EpiCept Corporation, a Delaware
corporation ("COMPANY"), the purchasers that are now and hereafter at any time
parties hereto and are listed in Annex A (or any amendment or supplement
thereto) attached hereto (each a "U.S. PURCHASER" and collectively, the "U.S.
PURCHASERS"), the purchasers that are now and hereafter at any time parties
hereto and are listed in Annex B (or any amendment or supplement thereto)
attached hereto (each a "QIB PURCHASER" and collectively, the "QIB PURCHASERS"),
and the purchasers that are now and hereafter at any time parties hereto and are
listed in Annex C (or any amendment or supplement thereto) attached hereto (each
a "REGULATION S PURCHASER" and, collectively, the "REGULATION S PURCHASERS" and
together with the U.S. Purchasers and the QIB Purchasers, the "PURCHASERS").
Capitalized terms used and not defined elsewhere in this Agreement are defined
in Article 1 hereof.

                                    RECITALS

A. On March 3, 2005, the Company and the Purchasers entered into the original
Note Purchase Agreement (the "ORIGINAL AGREEMENT") pursuant to which the Company
sold the Notes to the Purchasers in the aggregate principal amount of
$4,000,000.

B. The Company intends to enter into an agreement and plan of merger (the
"MERGER AGREEMENT") with Magazine Acquisition Corp. ("ACQUISITION CORP."), a
wholly owned subsidiary of the Company, and Maxim Pharmaceuticals Inc. ("MAXIM")
pursuant to which Acquisition Corp. will merge with and into Maxim (the
"MERGER"), with Maxim being the surviving corporation in the Merger.

C. The Company desires to amend and restate the Original Agreement to provide
for the conversion of the Notes held by TVM IV GMBH & CO. KG, ("TVM"), PRIVATE
EQUITY DIRECT FINANCE ("PRIVATE EQUITY"), THE MERLIN BIOSCIENCES FUND L.P. and
THE MERLIN BIOSCIENCES FUND GBR (collectively, the "MERLIN INVESTORS," and
together with TVM and Private Equity, the "CONVERTING HOLDERS") into shares of
Common Stock, $0.0001 par value of the Company (the "COMMON STOCK") effective
upon consummation of the Merger, subject to the terms and conditions set forth
in this Agreement.

D. In addition, in order to induce the Purchasers to purchase the Notes issued
pursuant to the Original Agreement, the Company issued and sold to the
Purchasers, in connection with the purchase of the Notes, warrants exercisable
for shares of Common Stock or Next Round Preferred Stock (as defined below), as
the case may be, subject to the terms and conditions set forth in this
Agreement. In connection with the execution of this Agreement, the warrants held
by Sanders Opportunity Fund, L.P. and Sanders Opportunity Fund (Institutional),
L.P. are also being amended and restated to provide for their automatic exercise
effective upon consummation of the Merger upon the terms and conditions set
forth therein.

     NOW, THEREFORE, the parties hereto, in consideration of the premises and
their mutual covenants and agreements herein set forth and intending to be
legally bound hereby, covenant and agree as follows:

                                    ARTICLE 1
                                   DEFINITIONS
<PAGE>
     1.1 CERTAIN DEFINITIONS. In addition to other words and terms defined
elsewhere in this Agreement, the following words and terms shall have the
meanings set forth below:

     "ACQUISITION CORP." shall have the meaning assigned to such term in the
preamble hereto.

     "AFFILIATE" shall mean, with respect to any Person, any other Person that
is directly or indirectly controlling, controlled by or under common control
with such Person or entity or any of its Subsidiaries, and the term "control"
(including the terms "CONTROLLED BY" and "UNDER COMMON CONTROL WITH") means
having, directly or indirectly, the power to direct or cause the direction of
the management and policies of a Person, whether through ownership of voting
securities, by contract or otherwise.

     "AGREEMENT" shall mean this Note Purchase Agreement, as the same may be
amended, restated, supplemented or otherwise modified from time to time.

     "BUSINESS DAY" shall mean any day other than a Saturday, Sunday or other
day on which banking institutions in New York City are authorized or required by
law to close.

     "BY-LAWS" shall mean, with respect to any Person, the by-laws, partnership
agreement, operating agreement, limited liability company agreement or analogous
instrument governing the operations of the Company, as applicable, including all
amendments and supplements thereto.

     "CURRENT CHARTER" shall mean the Amended and Restated Certificate of
Incorporation of the Company as of the date hereof and as amended from time to
time.

     "CLOSING" shall have the meaning assigned in Section 2.4 hereof.

     "CLOSING DATE" shall have the meaning assigned to such term in Section 2.4
hereof.

     "COMMON STOCK" shall have the meaning assigned to such term in the preamble
hereto.

     "DEFAULT" shall mean any event or condition that, but for the giving of
notice or the lapse of time, or both, would constitute an Event of Default.

     "EVENT OF DEFAULT" shall mean any of the events of default described in
Section 9.1 hereof.

     "FINANCIAL STATEMENTS" shall have the meaning assigned to such term in
Section 5.1(d) hereof.

     "GAAP" shall have the meaning assigned to such term in Section 1.2 hereof.

     "GUARANTEE" shall mean any guaranty of the payment or performance of any
Indebtedness or other obligation and any other arrangement whereby credit is
extended to one obligor on the basis of any promise of another Person, whether
that promise is expressed in terms of an obligation to pay the Indebtedness of
such obligor, or to purchase an obligation owed by such obligor, or to purchase
goods and services from such obligor pursuant to a take-or-pay contract, or to
maintain the capital, working capital, solvency or general financial condition
of such obligor, whether or not any such arrangement is reflected on the balance
sheet of such other Person, firm or corporation, or referred to in a footnote
thereto, but shall not include

                                        2
<PAGE>
endorsements of items for collection in the ordinary course of business. For the
purpose of all computations made under this Agreement, the amount of a Guarantee
in respect of any obligation shall be deemed to be equal to the maximum
aggregate amount of such obligation or, if the Guarantee is limited to less than
the full amount of such obligation, the maximum aggregate potential liability
under the terms of the Guarantee.

     "INDEBTEDNESS" shall mean, for any Person at the time of any determination,
without duplication, all obligations, contingent or otherwise, of such Person
that, in accordance with GAAP, should be classified upon the balance sheet of
such Person as indebtedness, but in any event including: (i) all obligations for
borrowed money, (ii) all obligations arising from installment purchases of
property or representing the deferred purchase price of property or services in
respect of which such Person is liable, contingently or otherwise, as obligor or
otherwise (other than trade payables and other current liabilities incurred in
the ordinary course of business on terms customary in the trade), (iii) all
obligations evidenced by notes, bonds, debentures, acceptances or instruments,
or arising out of letters of credit or bankers' acceptances issued for such
Person's account, (iv) all obligations, whether or not assumed, secured by any
Lien or payable out of the proceeds or production from any property or assets
now or hereafter owned or acquired by such Person, (v) all obligations for which
such Person is obligated pursuant to a Guarantee, (vi) the capitalized portion
of lease obligations under capital leases, (vii) all obligations for which such
Person is obligated pursuant to any Interest Rate Protection Agreements or
derivative agreements or arrangements, (viii) all factoring arrangements and
(ix) all obligations of such Person upon which interest charges are customarily
paid or accrued.

     "INTEREST RATE PROTECTION AGREEMENT" shall mean any interest rate swap,
interest rate cap, interest rate collar or other interest rate hedging agreement
or arrangement.

     "MAXIM" shall have the meaning assigned to such term in the preamble
hereto.

     "MERGER" shall have the meaning assigned to such term in the preamble
hereto.

     "MERGER AGREEMENT" shall have the meaning assigned to such term in the
preamble hereto.

     "NEXT ROUND PREFERRED STOCK" shall have the meaning assigned to such term
in the Warrants.

     "NOTE" shall have the meaning assigned to such term in Section 2.1(a)
hereof.

     "PERSON" shall mean any individual, partnership, limited partnership,
corporation, limited liability company, association, joint stock company, trust,
joint venture, unincorporated organization or governmental entity or department,
agency or political subdivision thereof.

     "PURCHASER" shall have the meaning assigned to such term in the preamble
hereto and, if applicable, in Section 7.2 hereof.

     "REGULATION S PURCHASER" shall have the meaning assigned to such term in
the preamble hereto.

                                        3
<PAGE>
     "REQUIRED PURCHASERS" shall mean, at any time, Purchasers holding a pro
rata percentage of the outstanding principal amount of the Notes aggregating at
least 66-2/3% at such time.

     "SEC" shall mean the Securities and Exchange Commission and any
governmental body or agency succeeding to the functions thereof.

     "SECURITIES" shall mean the Notes, the Warrants, the Warrant Shares and any
securities of the Company's capital stock issuable upon conversion of the Notes
and any securities which may be issuable upon exercise, conversion or exchange
of any of the foregoing.

     "SECURITIES ACT" shall mean the Securities Act of 1933, as amended.

     "SUBSIDIARY" of any corporation shall mean any other corporation or limited
liability company or other entity of which the outstanding capital stock or
equity interest possessing a majority of voting power in the election of
directors (otherwise than as the result of a default) is owned or controlled by
such corporation directly or indirectly through Subsidiaries.

     "TRANSACTION DOCUMENTS" shall mean this Agreement and the Securities and
all other agreements, instruments and documents delivered in connection
therewith as any or all of the foregoing may be supplemented or amended from
time to time.

     "TRANSACTIONS" shall mean the incurrence of debt and the issuance of
securities in connection therewith, as contemplated by this Agreement, the Notes
and all other agreements contemplated hereby and thereby.

     "U.S. PURCHASER" shall have the meaning assigned to such term in the
preamble hereto.

     "WARRANTS" shall have the meaning assigned to such term in Section 2.2
hereof.

     "WARRANT SHARES" shall mean the shares of Common Stock or Next Round
Preferred Stock issued or issuable upon exercise of the Warrants.

     1.2 ACCOUNTING PRINCIPLES. The character or amount of any asset, liability,
capital account or reserve and of any item of income or expense to be
determined, and any consolidation or other accounting computation to be made,
and the construction of any definition containing a financial term, pursuant to
this Agreement shall be determined or made in accordance with generally accepted
accounting principles in the United States of America consistently applied
("GAAP"), unless such principles are inconsistent with the express requirements
of this Agreement.

     1.3 OTHER DEFINITIONAL PROVISIONS; CONSTRUCTION. Whenever the context so
requires, neuter gender includes the masculine and feminine, the singular number
includes the plural and vice versa. The word "including" when used herein shall
mean "including without limitation" unless the context states otherwise. The
words "hereof," "herein" and "hereunder" and words of similar import when used
in this Agreement shall refer to this Agreement as a whole and not to any
particular provision of this Agreement, and references to any section, article,
annex, schedule, exhibit or like references are references to this Agreement
unless otherwise specified. A Default or Event of Default shall "continue" or be
"continuing" until such Default or Event of Default has been cured or waived by
any Purchaser as provided in

                                        4
<PAGE>
Section 9.2(b). References in this Agreement to any Persons shall include such
Persons, successors and permitted assigns. Other terms contained in this
Agreement (which are not otherwise specifically defined herein) shall have the
meanings provided to such terms in Article 9 of the New York Uniform Commercial
Code on the date hereof to the extent the same are used or defined therein.

                                    ARTICLE 2
                          ISSUE AND SALE OF SECURITIES

     2.1 NOTES. The Company has duly authorized the issuance to the Purchasers
of $4,000,000 of aggregate principal amount of the 8% Senior Notes due 2006, to
be substantially in the form of the promissory notes made by the Company in
favor of the Purchasers thereof in the form attached hereto as Exhibit A
(together with any promissory notes issued in substitution therefor pursuant to
Sections 7.3 and 7.4, the "NOTES").

     2.2 AUTHORIZATION AND ISSUANCE OF THE WARRANTS. The Company has duly
authorized the issuance and sale to the Purchasers certain stock purchase
warrants substantially in the form of the warrant attached hereto as Exhibit B
evidencing the Purchasers' right to acquire shares of Common Stock or Next Round
Preferred Stock, as the case may be (the "WARRANTS").

     2.3 SALE AND PURCHASE. Subject to the terms and conditions and in reliance
upon the representations, warranties and agreements set forth herein, (a) the
Company shall sell to the Purchasers, and the Purchasers shall purchase from the
Company, in the principal amounts designated in Annex A and Annex B, the Notes
for a purchase price equal to the principal amount and (b) the Company shall
sell to each Purchaser, and each Purchaser shall purchase from the Company, for
a total purchase price of $10.00, a Warrant.

     2.4 THE CLOSING. Delivery of and payment for the Securities to be issued at
closing (the "CLOSING") shall be made at the offices of Weil, Gotshal & Manges
LLP, 767 Fifth Avenue, New York, NY 10153, commencing at 10:00 a.m., local time,
on March 3, 2005 or at such place or on such other date as may be mutually
agreeable to the Company and the Purchasers. The date and time of the Closing as
finally determined pursuant to this Section 2.4 are referred to herein as the
"CLOSING DATE." Delivery of the Securities shall be made to the Purchasers
against payment of the purchase price therefor by wire transfer of immediately
available funds in the manner agreed to by the Company and the Purchasers. The
Notes and Warrants to be issued at Closing shall be issued in such name or names
and in such permitted denomination or denominations, numbers and amounts as set
forth in Annex A or Annex B or as the Purchasers may request in writing not less
than two (2) Business Days before the Closing Date.

     2.5 DELIVERY OF THE CERTIFICATES REPRESENTING THE NOTES TO REGULATION S
PURCHASERS. At the Closing, the Company will issue a temporary global
certificate representing the aggregate principal amount of the Notes being
purchased by the Regulation S Purchasers, registered in the name of EpiCept
Corporation, on behalf of the Regulation S Purchasers, which shall be held in
trust by the Company for the benefit of each of the Regulation S Purchasers
until the Delivery Date (as hereinafter defined). The Company will cause to be
delivered to each Regulation S Purchaser or its nominee who is acting as its
custodian, without additional payment, within five (5) Business Days following
the Delivery Date, one (1) or more definitive certificates representing the
aggregate principal amount of the Notes purchased by such

                                        5
<PAGE>
Regulation S Purchaser registered in the name of such Regulation S Purchaser or
its nominee who is acting as its custodian. The Delivery Date is the first
business day following a period of forty (40) days after the Closing Date.

                                    ARTICLE 3
                               REPAYMENT OF NOTES

     3.1 INTEREST RATES.

          (a) The Notes shall bear interest on the outstanding principal thereof
at a rate per annum equal to eight percent (8%).

          (b) Interest on the Notes will be computed on the basis of a year
within three hundred sixty (360) days, and the actual number of days elapsed.

     3.2 REPAYMENT OF NOTES. The Company covenants and agrees to pay all
outstanding principal and accrued and unpaid interest.

     3.3 OPTIONAL PREPAYMENT OF NOTES. The Company shall have the right at its
option at any time to prepay the outstanding principal and accrued and unpaid
interest on the Notes, in whole or in part, without premium or penalty; provided
that the Company notifies the affected Purchasers of the date that it intends to
make payment on the Note not less than five (5) Business Days prior to such
date. Any prepayment of the Notes shall be accompanied by the interest accrued
and unpaid on the prepaid principal amount. Notice of prepayment having been so
given, the aggregate principal amount of the Notes specified in such notice,
together with accrued interest thereon and the premium, if any, shall become due
and payable on the prepayment date set forth in such notice.

     3.4 MANDATORY PREPAYMENT. The Notes shall be prepaid in full, together with
all accrued and unpaid interest, (1) within five (5) Business Days of the
consummation of any public offering of debt or equity securities of the Company
or (2) immediately upon the consummation of Sale of the Company (each a
"MANDATORY PREPAYMENT EVENT"). For purposes hereof, a "SALE OF THE COMPANY"
means (a) a merger, consolidation, share exchange or other form of corporate
reorganization involving the Company in which the stockholders of the Company
immediately before such merger, consolidation, share exchange or other corporate
reorganization dispose of in excess of fifty percent (50%) of the issued and
outstanding capital stock of the Company; (b) any transaction or series of
related transactions in which (i) all or substantially all of the assets of the
Company are sold, or (ii) in excess of fifty percent (50%) of the shares of
Common Stock (assuming conversion of all convertible securities) is issued
transferred to any person; or (c) any event that would trigger payments to the
holders of any series of the Company's Preferred Stock under Section 1(c) of
Article FOURTH of the Current Charter in the absence of the prescribed vote of
the holders of such series to the contrary. The Company will mail or cause to be
mailed to the holder of the Notes a notice specifying the date on which such
Mandatory Prepayment Event is scheduled to be consummated. Such notice will be
mailed at least twenty (20) days prior to the date of such consummation.

     3.5 CONVERSION UPON MERGER.

          (a) Immediately prior to the Effective Time of the Merger, the
outstanding principal of and accrued and unpaid interest on the Notes held by
the Converting Holders shall

                                        6
<PAGE>
automatically convert, without further act on the part of such Purchasers, into
shares of Common Stock at a conversion price of $0.71.

          (b) Immediately following such conversion, all Warrants issued to the
Converting Holders shall be void and of no further force and effect without any
further action on the part of such Purchaser or the Company.

          (c) In the event that conversion of a Note would, but for the
provisions of this Section 3.5(b), result in the issuance of any fractional
share of Common Stock, such fractional shares shall be rounded up to the next
nearest whole number of shares of Common Stock.

                                    ARTICLE 4
                                   CONDITIONS

     4.1 CONDITIONS TO THE PURCHASE OF SECURITIES. The obligation of Purchasers
to purchase and pay for the Securities to be purchased at the Closing is subject
to the satisfaction, prior to or at the Closing, of the following conditions:

          (a) REPRESENTATIONS AND WARRANTIES TRUE. The representations and
warranties of the Company contained in Article 5 hereof shall be true and
correct at and as of the Closing Date as though then made.

          (b) AGREEMENTS AND CONDITIONS. The Company shall have performed and
complied with all agreements, obligations and conditions contained in this
Agreement that are required to be performed or complied with by it on or before
the Closing Date.

          (c) CLOSING DOCUMENTS. Except as set forth in Section 2.5, the Company
will have delivered the following documents in form and substance reasonably
satisfactory to the Purchasers:

               (i) Notes in aggregate original principal amounts as set forth
          herein, duly completed and executed by the Company;

               (ii) one or more Warrants evidencing the right to acquire shares
          of Common Stock or Next Round Preferred Stock of the Company;

               (iii) certificates of good standing dated not more than ten (10)
          days prior to the Closing Date for the Company issued by the Secretary
          of State of the State of Delaware and each jurisdiction where it is
          qualified to operate as a foreign corporation, or its equivalent;

               (iv) a copy of the Current Charter of the Company, certified by
          the Secretary of State of the State of Delaware as of a date not more
          than ten (10) days prior to the Closing Date;

               (v) a copy of the By-laws of the Company, certified as of the
          Closing Date by the secretary or assistant secretary of the Company;

                                        7
<PAGE>
               (vi) a certificate of the secretary or assistant secretary of the
          Company, certifying as to the names and true signatures of the
          officers of the Company authorized to sign this Agreement and the
          other documents to be delivered by the Company hereunder;

               (vii) copies of the resolutions duly adopted by the Company's
          board of directors authorizing the execution, delivery and performance
          by the Company of this Agreement and each of the other agreements,
          instruments and documents contemplated hereby to which it is a party,
          and the consummation of all of the other Transactions, certified as of
          the Closing Date by the secretary or assistant secretary of the
          Company;

               (viii) a certificate dated as of the Closing Date from an officer
          of the Company stating that the conditions specified in this Section
          4.1 have been fully satisfied or waived by the Purchasers; and

               (ix) such other documents contemplated by this Agreement as the
          Purchasers or their counsel may reasonably request.

          (d) WAIVER OF RIGHT OF FIRST REFUSAL. The Waiver by Investors of
Certain Rights of First Refusal (currently in the form attached hereto as
Exhibit C) shall have been duly and validly executed by the Company and all
signatories thereto.

          (e) PROCEEDINGS. All proceedings taken or required to be taken in
connection with the transactions contemplated hereby to be consummated at or
prior to the Closing and all documents incident thereto will be reasonably
satisfactory in form and substance to the Purchasers and their counsel.

          (f) SECOND AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT. The
Company, the Purchasers and certain other securityholders of the Company, shall
have entered into the Second Amended and Restated Registration Rights Agreement,
dated as of March 3, 2005 in form and substance as set forth in Exhibit D
attached hereto (the "REGISTRATION RIGHTS AGREEMENT").

     4.2 WAIVER. Any condition specified in this Article 4 may be waived by the
Purchasers.

                                    ARTICLE 5
               REPRESENTATIONS AND WARRANTIES OF THE LOAN PARTIES

     5.1 REPRESENTATIONS AND WARRANTIES OF THE COMPANY. The Company represents
and warrants to the Purchasers as follows:

          (a) The Company is a corporation duly organized, validly existing and
in good standing under the laws of the State of Delaware, and has the corporate
power and authority to own, lease and operate its properties and to conduct the
business that it presently conducts. The Company is duly qualified as a foreign
corporation to transact business, and is in good standing in each jurisdiction
in which such qualification is required, except for such jurisdictions where the
failure to be so qualified or in good standing would not have a material

                                        8
<PAGE>
adverse effect on the condition, financial or otherwise, or on the results of
operations, business affairs or business prospects of the Company.

          (b) The execution, delivery and performance of this Agreement by the
Company (a) has been duly authorized and approved by the Board of Directors of
the Company and all other necessary corporate action on the part of the Company
in connection therewith has been taken, and (b) will not conflict with or
constitute a breach of or default under, or result in the creation or imposition
of any lien, charge or encumbrance upon any property or assets of the Company
pursuant to (i) the charter documents or by-laws of the Company, (ii) any
material contract, indenture, mortgage, loan agreement, note, lease or other
agreement or instrument to which the Company is a party or by which it may be
bound or to which any of its properties may be subject, or (iii) any law,
administrative regulation or court decree applicable to or binding upon the
Company. This Agreement, the Notes, the Warrants and the Registration Rights
Agreement have been duly and validly executed and delivered by the Company and
constitute the legal, valid and binding agreement of the Company, enforceable
against the Company in accordance with its terms, except that (i) any
enforcement may be subject to bankruptcy, insolvency, reorganization, moratorium
or similar laws from time to time in effect and affecting the rights of
creditors generally, (ii) the remedy of specific performance and injunctive and
other forms of equitable relief may be subject to equitable defenses and to the
discretion of the court before which any proceedings therefor may be brought and
(iii) the enforcement of rights to indemnity and contribution under the
Registration Rights Agreement may be limited by applicable securities laws or
principles of public policy.

          (c) No authorization, approval or consent of any court, governmental
authority or agency is necessary with respect to the issuance by the Company of
the Note or Warrant.

          (d) The audited consolidated balance sheet of the Company as of
December 31, 2004, and the related audited consolidated statement of income,
stockholders' equity and cash flows for the Company for the year ended December
31, 2004, have been made available to the Purchasers (such financial statements
are referred to herein as the "FINANCIAL STATEMENTS"; the balance sheet of the
Company as of December 31, 2004 is hereinafter referred to as the "BALANCE
SHEET," and December 31, 2004 is hereafter referred to as the "BALANCE SHEET
DATE"). The Financial Statements (a) are true and correct in all material
respects, (b) are in accordance with the books and records of the Company, and
(c) present fairly the financial position and results of operations of the
Company as of the dates and for the periods indicated in accordance with
generally accepted accounting principles applied on a consistent basis.

          (e) Since the Balance Sheet Date there has not been (a) any material
adverse change in the financial condition, results of operations, assets,
liabilities, business or prospects of the Company, other than in connection with
the deterioration of the Company's cash position in line with the Company's
forecasts existing as at the Balance Sheet Date, (b) any material asset or
property of the Company made subject to a lien of any kind, except liens for
taxes not yet due and payable, (c) any waiver of any valuable right of the
Company, or the cancellation of any debt or claim held by the Company, (d) any
payment of dividends on, or other distribution with respect to, or any direct or
indirect redemption or acquisition of, any shares of the capital stock of the
Company, or any agreement or commitment therefor, (e) any mortgage, pledge,
sale, assignment or transfer of any tangible or intangible assets of the
Company, except in the ordinary course of business, (f) any loan by the Company
to, or any loan to the Company from, any

                                        9
<PAGE>
officer, director, employee or stockholder of the Company, or any agreement or
commitment therefor except for the issuance of the Notes, (g) any damage,
destruction or loss (whether or not covered by insurance) materially and
adversely affecting the assets, property or business of the Company, or (h) any
change in the accounting methods or practices followed by the Company.

          (f) As of the Closing Date and immediately thereafter, the authorized
capital stock of the Company will be as set forth on Schedule 5.1(f). Except as
set forth on Schedule 5.1(f), as of the Closing Date, the Company will not have
outstanding any stock or securities convertible into or exchangeable for any
shares of its capital stock and will not have outstanding any rights or options
to subscribe for or to purchase its capital stock or any stock or securities
convertible into or exchangeable for its capital stock. As of the Closing Date,
the Company will not then be subject to any obligation to repurchase or
otherwise acquire or retire any shares of its capital stock. As of the Closing
Date, all of the outstanding shares of the Company's capital stock will be
validly issued, fully paid and nonassessable. The Company has not violated any
applicable federal or state securities laws in connection with the offer, sale
or issuance of any of its capital stock, and based upon the Purchasers'
representations, warranties and covenants in Article 6 hereof, the offer, sale
and issuance of the Notes and the Warrants hereunder do not require registration
under the Act or any applicable state securities laws. Except as set forth on
Schedule 5.1(f), there are no agreements among the Company's stockholders with
respect to the voting or transfer of the Company's capital stock.

                                    ARTICLE 6
                REPRESENTATIONS AND WARRANTIES BY THE PURCHASERS

     6.1 REPRESENTATIONS AND WARRANTIES OF THE PURCHASERS. Each of the
Purchasers hereby represent and warrant to the Company as follows:

          (a) Such Purchaser acknowledges that he/she/it had access to the
Financial Statements. Such Purchaser further acknowledges that he/she/it fully
understands the Financial Statements, and has had the opportunity to discuss any
questions regarding the Financial Statements with his/her/its counsel or other
legal, financial and tax advisors. Such Purchaser acknowledges that he/she/it
has received no representations or warranties from the Company or its respective
employees or agents in making this investment decision other than as set forth
in the Financial Statements, this Agreement, the Note and the Warrant.

          (b) Such Purchaser recognizes that the purchase of the Note and the
Warrant entails elements of risk in that (i) the Purchaser may not be able
readily to liquidate the investment; (ii) transferability of the Securities are
restricted; and (iii) the Purchaser could sustain the loss of their entire
investment.

          (c) Such Purchaser (other than the QIB Purchasers and the Regulation S
Purchasers) is an "accredited investor" within the meaning ascribed to such term
in Rule 501 of Regulation D under the Securities Act.

          (d) Such Purchaser hereby represents that he/she/it has prior
investment experience such that the Purchaser is able to evaluate the merits and
risks of an investment in the Company, or that the Purchaser has employed the
services of an investment advisor to read the Financial Statements and to
evaluate the merits and risks of such an investment on the Purchaser's behalf,
and that the Purchaser recognizes the speculative nature of this investment and
acknowledges that the Purchaser is able to bear the economic risks being assumed
by the

                                       10
<PAGE>
Purchaser. The Purchaser also acknowledges that the Purchaser and its
representative(s) have been afforded the opportunity to make, and have made, all
inquiries as the Purchaser and its representatives deemed appropriate with
respect to the Company's affairs and prospects.

          (e) The Purchaser hereby represents that such Purchaser is acquiring
the Note and the Warrant for the Purchaser's own account for purposes of
investment and not with a view to or in connection with the distribution or
resale of all or any part thereof, and that such Purchaser does not have any (1)
present intention of selling, transferring, granting any participation in, or
otherwise distributing the Note or the Warrant, or (2) contract, undertaking,
agreement or arrangement with any person or entity to sell, transfer, grant any
participation in or otherwise distribute all or any part of the Note or the
Warrant. The Purchaser understands that the Note and the Warrant will not be
registered under the Act or applicable state securities laws by reason of
specific exemptions therefrom, which exemptions depend upon, among other things,
the Purchaser's representations set forth herein.

          (f) The Purchaser hereby represents that any shares issuable upon the
conversion of the Note and the exercise of the Warrant, is and will be acquired
by the Purchaser for such Purchaser's own account for purposes of investment and
not with a view to or in connection with the distribution or resale of all or
any part thereof, and that such Purchaser does not have any (1) present
intention of selling, transferring, granting any participation in, or otherwise
distributing such securities, or (2) contract, undertaking, agreement or
arrangement with any person or entity to sell, transfer, grant any participation
in or otherwise distribute all or any part of such securities. The Purchaser
understands that such securities will not be registered under the Act or
applicable state securities laws by reason of specific exemptions therefrom,
which exemptions depend upon, among other things, the Purchaser's
representations set forth herein.

          (g) The Purchaser hereby represents that such Purchaser has not been
organized for the purpose of acquiring the Securities.

          (h) The Purchaser understands that the Securities are characterized as
"restricted securities" under the Act inasmuch as they are being acquired from
the Company in a transaction not involving a public offering, and that the
Securities may be resold without registration under the Act only in certain
limited circumstances. In connection therewith, the Purchaser represents that
such Purchaser is familiar with Rule 144 of the Act, as presently in effect, and
understands the resale limitations imposed thereby and by the Act.

     6.2 ADDITIONAL REPRESENTATIONS AND WARRANTIES OF THE QIB PURCHASERS. Each
of the QIB Purchasers also hereby represent and warrant to the Company as of the
date hereof, the Closing Date and on the Delivery Date, as follows:

          (a) Such QIB Purchaser is a "qualified institutional buyer" within the
meaning ascribed to such term in Rule 144A under the Securities Act.

     6.3 ADDITIONAL REPRESENTATIONS AND WARRANTIES OF THE REGULATION S
PURCHASERS. Each of the Regulation S Purchasers also hereby represent and
warrant to the Company as of the date hereof, the Closing Date and on the
Delivery Date, as follows:

          (a) Such Regulation S Purchaser understands and acknowledges that (a)
the Securities may not be offered, sold, transferred, pledged or otherwise
disposed of, in the United

                                       11
<PAGE>
States or to, or for the account or benefit of, any "U.S. person," unless such
securities are registered under the Securities Act and any applicable state
securities or blue sky laws or exemptions from the registration requirements of
such laws are available, (b) the Securities are being offered and sold in a
manner intended to comply with the conditions contained in Regulation S, which
permits securities to be sold to persons who are not "U.S. persons" in "offshore
transactions" (as defined in Regulation S), subject to certain terms and
conditions and (c) such Regulation S Purchaser is not purchasing the Securities
in any transaction or series of transactions that, although in technical
compliance with Regulation S, is part of a plan or scheme to evade the
registration provisions of the Securities Act.

          (b) Such Regulation S Purchaser nor any person or account as to which
it exercises investment discretion for investment purposes only and not for any
trading or arbitrage purposes is a "U.S. person" or is acquiring the Securities
for the account or benefit of a "U.S. person."

                                    ARTICLE 7
                             TRANSFER OF SECURITIES

     7.1 RESTRICTED SECURITIES. The Purchasers acknowledge that the Securities
have not been registered or qualified under the Securities Act or applicable
foreign or state securities laws and may not be transferred or otherwise
disposed of unless they have been so registered or qualified or if an opinion of
counsel satisfactory to the Company to the effect that such registration and
qualification is not required has been delivered to the Company, and that except
as specifically provided in the Registration Rights Agreement, the Company is
not required to register any of the Securities under the Securities Act.

     7.2 LEGENDS. The Company may place an appropriate legend on the Securities
concerning the restrictions set forth in this Article 7 and by applicable law.
Upon the assignment or transfer by the Purchasers or any of their respective
successors or assigns of all or any part of the Securities, the term "Purchaser"
as used herein shall thereafter mean, to the extent thereof, the then holder or
holders of such Securities, or portion thereof.

     7.3 TRANSFER OF NOTES.

          (a) Subject to Section 7.2 and Section 7.3(b), a holder of a Note may
transfer such Note to a new holder, or may exchange such Note for Notes of
different denominations (but in no event for denominations of less than $100,000
in original principal amount), by surrendering such Note to the Company duly
endorsed for transfer or accompanied by a duly executed instrument of transfer
naming the new holder (or the current holder if submitted for exchange only),
together with written instructions for the issuance of one or more new Notes
specifying the respective principal amounts of each new Note and the name of
each new holder and each address therefor. The Company shall simultaneously
deliver to such holder or its designee such new Notes, shall mark the
surrendered Notes as canceled. In lieu of the foregoing procedures, a holder may
assign a Note (in whole but not in part) to a new holder by sending written
notice to the Company of such assignment specifying the new holder's name and
address; in such case, the Company shall promptly acknowledge such assignment in
writing to both the old and new holder. Any transferees shall be subject to
Sections 7.1, 7.2 and 7.3(b).

          (b) For a period (the "NOTES RESTRICTED PERIOD") of forty (40) days
following the Closing Date (which Notes Restricted Period shall expire not
earlier than midnight (New

                                       12
<PAGE>
York time) on the Delivery Date) with respect to the Notes and for a period (the
"WARRANTS RESTRICTED PERIOD", and together with the Notes Restricted Period, the
"RESTRICTED PERIODS") of one (1) year following the Closing Date (which Warrants
Restricted Period shall expire not earlier than midnight (New York time) on the
first anniversary of the date hereof) with respect to the Warrants, no
Regulation S Purchaser shall engage in any activity for the purpose of, or which
may reasonably be expected to have the effect of, conditioning the market in the
United States for the Notes or Warrants, as the case may be, or offer, sell,
transfer, pledge or otherwise dispose of the Notes or Warrants, as the case may
be, in the United States or to, or for the account or benefit of, a "U.S.
person". Each Regulation S Purchaser understands and agrees that the Notes and
the Warrants are only transferable on the books and records of the Company and
its transfer agent, if applicable, and that the Company and its transfer agent
will not register any transfer of the Notes and/or Warrants which the Company in
good faith believes violates the restrictions set forth herein.

Any proposed offer, sale, transfer, pledge or other disposition of any of the
Notes or Warrants prior to the expiration of their respective Restricted Periods
shall be subject to the condition that such Regulation S Purchaser must deliver
to the Company (i) a written certification that the Notes and/or Warrants have
not been offered or sold in the United States or to, or for the account or
benefit of, any "U.S. person" by such Regulation S Purchaser, (ii) a written
certification of the proposed transferee that such transferee (or any account
for which such transferee is acquiring such Notes and/or Warrants) is not a
"U.S. person," is not acquiring the Notes and/or Warrants for the account or
benefit of any "U.S. person," is acquiring such Notes and/or Warrants for such
transferee's own account (or an account over which it has investment discretion)
for investment purposes only and not for any trading or arbitrage purposes and
not with a view to, or for sale in connection with, any distribution of the
Notes and/or Warrants at any particular time or at any particular price, and
that such transferee is knowledgeable of and agrees to be bound by the
provisions of Regulation S and the terms of this Section 7.3(b) during the
Restricted Periods and, (iii) a written opinion of United States legal counsel,
in form and substance satisfactory to the Company, to the effect that such
offer, sale, transfer, pledge or other disposition of such Notes and/or Warrants
is exempt from registration under the Securities Act. Such Regulation S
Purchaser will not, directly or indirectly, offer, sell, pledge, transfer or
otherwise dispose of (or solicit any offers to buy, purchase or otherwise
acquire or take pledge of) its rights under this Agreement or the Notes and/or
Warrants otherwise than in compliance with the Securities Act, any applicable
state securities or blue sky laws and any applicable securities laws of
jurisdiction outside the United States, and the rules and regulations
promulgated thereunder.

     7.4 REPLACEMENT OF LOST SECURITIES. Upon receipt of evidence reasonably
satisfactory to the Company of the mutilation, destruction, loss or theft of any
Securities and the ownership thereof, the Company shall, upon the written
request of the holder of such Securities, execute and deliver in replacement
thereof new Securities in the same form, in the same original tenor and dated
the same date as the Securities so mutilated, destroyed, lost or stolen; and
such Securities so mutilated, destroyed, lost or stolen shall then be deemed no
longer outstanding hereunder. If the Securities being replaced have been
mutilated, they shall be surrendered to the Company; and if such replaced
Securities have been destroyed, lost or stolen, such holder shall furnish the
Company with an indemnity in writing to save the Company harmless in respect of
such replaced Securities.

                                       13
<PAGE>
     7.5 NO OTHER REPRESENTATIONS AFFECTED. Nothing contained in this Article 7
shall limit the full force or effect of any representation, agreement or
warranty made herein or in connection herewith to the Purchasers.

                                    ARTICLE 8
                                    COVENANTS

     8.1 LIMITATION ON INDEBTEDNESS. The Company covenants that, so long as all
or any part of the Notes shall remain outstanding it shall not create, incur,
assume guarantee or be or remain liable for, contingently or otherwise, or
suffer to exist any Indebtedness, except:

          (a) Indebtedness under this Agreement;

          (b) Indebtedness incurred in the ordinary course of business with
respect to customer deposits, trade payables and other unsecured current
liabilities not the result of borrowing and not evidenced by any note or other
evidence of indebtedness;

          (c) Indebtedness under Capital Leases;

          (d) Indebtedness with respect to Guarantees;

          (e) Intercompany Indebtedness between and among the Company and its
Subsidiaries; and

          (f) Indebtedness listed on the Permitted Indebtedness Schedule
attached hereto as Schedule 8.1, and extensions, renewals and replacements
thereof which do not increase the amount of such Indebtedness as of the date of
such extension, replacement or renewal; provided that if such Indebtedness is
subordinated to the Notes on the date hereof that it continues to be
subordinated to the Notes on terms no less favorable than such Indebtedness is
subordinated to the Notes on the date hereof.

                                    ARTICLE 9
                                EVENTS OF DEFAULT

     9.1 EVENTS OF DEFAULT. If any of the following events ("EVENTS OF DEFAULT")
shall occur:

          (a) A final judgment or settlement shall be rendered against or agreed
to by the Company or any of its subsidiaries for the payment of money that,
after deducting the amount of any insurance proceeds paid or payable to or on
behalf of the Company or such subsidiary in connection with such judgment or
settlement, as the case may be, is in excess of $50,000, and such judgment shall
remain undischarged for a period of thirty (30) days, during which period
execution shall not effectively be stayed, or such settlement shall remain
unpaid for a period of thirty (30) days after the agreed payment date unless
such delay has been agreed to by the other party. If a dispute exists with
respect to the liability of any insurance underwriter under any insurance policy
of the Company or such subsidiary, no deduction under this subsection shall be
made for any portion of the insurance proceeds that are the subject of such
dispute;

          (b) The Company or any of its subsidiaries shall (i) voluntarily
terminate operations or apply for or consent to the appointment of, or the
taking of possession by, a

                                       14
<PAGE>
receiver, custodian, trustee or liquidator of it or of all or a substantial part
of its assets, (ii) admit in writing its inability, or be generally unable, to
pay its debts as the debts become due, (iii) make, or enter into negotiations to
make, a general assignment for the benefit of its creditors, (iv) commence a
voluntary case under the Federal Bankruptcy Code of the United States (as now or
hereafter in effect), (v) file a petition (relating to itself) seeking to take
advantage of any other law relating to bankruptcy, insolvency, reorganization,
winding up, or composition or adjustment of debts, (vi) fail to controvert in a
timely and appropriate manner, or acquiesce in writing to, any petition filed
against it in an involuntary case under the Federal Bankruptcy Code of the
United States or other applicable bankruptcy law or (vii) take any corporate
action for the purpose of effecting any of the foregoing;

          (c) Without its application, approval or consent, a proceeding shall
be commenced, in any court of competent jurisdiction, seeking in respect of the
Company or any of its subsidiaries the liquidation, reorganization, dissolution,
winding up, or composition or readjustment of debt, the appointment of a
trustee, receiver, liquidator or the like of such entity or of all or any
substantial part of its assets, or other like relief in respect of such entity
under any law relating to bankruptcy, insolvency, reorganization, winding up, or
composition or adjustment of debts; and, if the proceeding is being contested in
good faith by such entity, the same shall continue undismissed, or unstayed and
in effect for any period of forty-five (45) consecutive days, or an order for
relief against such entity shall be entered in any case under the Federal
Bankruptcy Code of the United States or other applicable bankruptcy law;

          (d) Any foreclosure or other proceedings shall be commenced to
enforce, execute or realize upon any lien, encumbrance, attachment, trustee
process, mortgage or security interest for payment of an amount in excess of
$50,000 against the Company or any of its subsidiaries;

          (e) There shall occur any default not cured within the applicable
grace period under any instrument or agreement evidencing any indebtedness in
excess of $500,000 for money borrowed by the Company or any of its subsidiaries;

          (f) There shall occur any acceleration or any default not cured within
the applicable grace period under any of the agreements relating to the loans to
the Company or EpiCept GmbH from IKB or Technologie-Beteiligungs-Gesellschaft
mbH der Deutschen Ausgleichsbank;

          (g) There shall occur any merger, consolidation, share exchange or
other form of corporate reorganization involving the Company in which the
stockholders of the Company immediately before such merger, consolidation, share
exchange or other corporate reorganization dispose of in excess of fifty percent
(50%) of the issued and outstanding capital stock of the Company;

          (h) There shall occur any transaction or series of related
transactions in which (i) all or substantially all of the assets of the Company
are sold, or (ii) in excess of fifty percent (50%) of the shares of Common Stock
(assuming conversion of all convertible securities) is issued transferred to any
person (other than in a Qualifying Financing or a Qualified Public Offering); or

          (i) There shall occur any event that will trigger payments to the
holders of any series of the Preferred Stock under Section 1(c) of Article
FOURTH of the Current Charter

                                       15
<PAGE>
in the absence of the prescribed vote of the holders of such series to the
contrary[, other than the Merger.].

     9.2 CONSEQUENCES OF EVENT OF DEFAULT.

          (a) BANKRUPTCY. If an Event of Default specified in paragraphs (b) or
(c) of Section 9.1 hereof shall occur, the unpaid principal of the Notes, all
interest accrued and unpaid thereon and all other liabilities of the Company
hereunder and thereunder shall be immediately due and payable, without
presentment, demand, protest or (except as expressly required hereby) notice of
any kind, all of which are hereby expressly waived.

          (b) OTHER DEFAULTS. If any other Event of Default shall occur, any
Purchaser (without the agreement of any other Purchaser) may at its option, by
written notice to the Company and the other Purchasers, declare the entire
unpaid balance of the Notes, all interest accrued thereon and all other
liabilities of the Company hereunder and thereunder to be forthwith due and
payable, and the same shall thereupon become immediately due and payable,
without presentment, demand, protest or (except as expressly required hereby)
notice of any kind, all of which are hereby expressly waived; provided that if a
Default specified in clause (ii) of paragraph (b) of Section 9.1 hereof shall
occur, any holder of a Note as to which such Event of Default has occurred may
declare the entire unpaid balance of such Note (but only such Note) and other
amounts due hereunder and thereunder with respect to such Note immediately due
and payable and same shall thereupon become immediately due and payable, without
presentment, demand, protest or (except as expressly provided hereby) notice of
any kind, all of which are expressly waived.

          (c) DEFAULT INTEREST. Following the occurrence and during the
continuance of any Event of Default, the holders of the Notes shall be entitled
to receive, to the extent permitted by applicable law, interest on the
outstanding principal of, and premium and overdue interest, if any, on, the
Notes at a rate per annum equal to the interest rate thereon (determined as
provided in Section 3.1) plus two hundred (200) basis points.

                                   ARTICLE 10
                                  MISCELLANEOUS

     10.1 SUCCESSORS AND ASSIGNS. This Agreement shall be binding upon and inure
to the benefit of the parties hereto and their respective successors and
assigns, except that (i) the Company may not assign or transfer its rights
hereunder or any interest herein or delegate its duties hereunder and (ii) the
Purchasers shall have the right to assign their rights hereunder and the
Securities in accordance with Article 7.

     10.2 MODIFICATIONS AND AMENDMENTS. The provisions of this Agreement may be
modified, waived or amended, but only by a written instrument signed by the
Company, and to the extent such modification, amendment or waiver relates (i) to
the Notes, such instrument must be executed by the Required Purchasers and (ii)
to the Warrants or the Warrant Shares, such instrument must be executed by the
holders of seventy-five percent (75%) of the Warrant Shares.

     10.3 NO IMPLIED WAIVERS; CUMULATIVE REMEDIES; WRITING REQUIRED. No delay or
failure in exercising any right, power or remedy hereunder shall affect or
operate as a waiver thereof; nor shall any single or partial exercise thereof or
any abandonment or discontinuance of steps to enforce such a right, power or
remedy preclude any further exercise thereof or of any

                                       16
<PAGE>
other right, power or remedy. The rights and remedies hereunder are cumulative
and not exclusive of any rights or remedies that the Purchasers or any holder of
Notes, Warrants or Warrant Shares would otherwise have. Any waiver, permit,
consent or approval of any kind or character of any breach or default under this
Agreement or any such waiver of any provision or condition of this Agreement
must be in writing and shall be effective only to the extent in such writing
specifically set forth.

     10.4 REIMBURSEMENT OF EXPENSES. The Company agrees to pay or reimburse the
Purchasers upon demand for all reasonable out-of-pocket fees and expenses
incurred or payable by the Purchasers (including, without limitation, reasonable
due diligence expenses and fees and expenses of counsel for the Purchasers) up
to a maximum amount of $10,000.

     10.5 HOLIDAYS. Whenever any payment or action to be made or taken hereunder
or under the Notes shall be stated to be due on a day that is not a Business
Day, such payment or action shall be made or taken on the next following
Business Day, and such extension of time shall be included in computing interest
or fees, if any, in connection with such payment or action.

     10.6 NOTICES. All notices and other communications given to or made upon
any party hereto in connection with this Agreement shall, except as otherwise
expressly herein provided, be in writing (including telecopy, but in such case,
a confirming copy will be sent by another permitted means) and mailed via
certified mail, telecopied or delivered by guaranteed overnight parcel express
service or courier to the respective parties, as follows:

     to the Company:

     EpiCept Corporation
     270 Sylvan Avenue
     Englewood Cliffs, New Jersey 07632
     Facsimile: (201) 837-0200
     Attention: Chief Financial Officer

     with a copy to:

     Weil, Gotshal & Manges LLP
     767 Fifth Avenue
     New York, New York 10153
     Facsimile: (212) 310-8007
     Attention: Alexander D. Lynch, Esq.

     to Purchasers:

     As set forth on Annex A or Annex B.

or in accordance with any subsequent written direction from the recipient party
to the sending party. All such notices and other communications shall, except as
otherwise expressly herein provided, be effective upon delivery if delivered by
courier or overnight parcel express service; in the case of certified mail,
three (3) Business Days after the date sent; or in the case of telecopy, when
received.

                                       17
<PAGE>
     10.7 SURVIVAL. This Agreement shall terminate upon conversion or repayment
of all Notes issued hereunder and the exercise of all Warrants issued in
connection with such Notes. All obligations relating to indemnification
hereunder shall survive any termination of this Agreement and shall continue for
the length of any applicable statute of limitations.

     10.8 GOVERNING LAW. THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN
ACCORDANCE WITH, THE AS OF THE STATE OF DELAWARE, WITHOUT REGARD TO CONFLICT OF
LAWS PRINCIPLES.

     10.9 JURISDICTION, CONSENT TO SERVICE OF PROCESS.

          (a) THE COMPANY HEREBY IRREVOCABLY AND UNCONDITIONALLY SUBMITS, FOR
ITSELF AND ITS PROPERTY, TO THE NONEXCLUSIVE JURISDICTION OF ANY DELAWARE STATE
COURT OR FEDERAL COURT OF THE UNITED STATES OF AMERICA SITTING IN THE STATE OF
DELAWARE, AND ANY APPELLATE COURT FROM ANY THEREOF, IN ANY ACTION OR PROCEEDING
ARISING OUT OF OR RELATING TO THIS AGREEMENT, THE NOTES OR ANY OTHER TRANSACTION
DOCUMENT, OR FOR RECOGNITION OR ENFORCEMENT OF ANY JUDGMENT, AND EACH OF THE
PARTIES HERETO HERBY IRREVOCABLY AND UNCONDITIONALLY AGREES THAT, TO THE EXTENT
PERMITTED BY APPLICABLE LAW, ALL CLAIMS IN RESPECT OF ANY SUCH ACTION OR
PROCEEDING MAY BE HEARD AND DETERMINED IN SUCH STATE COURT OR, TO THE EXTENT
PERMITTED BY LAW, IN SUCH FEDERAL COURT. EACH OF THE PARTIES HERETO AGREES THAT
A FINAL JUDGMENT IN ANY SUCH ACTION OR PROCEEDING SHALL BE CONCLUSIVE AND MAY BE
ENFORCED IN OTHER JURISDICTIONS BY SUIT ON THE JUDGMENT OR IN ANY OTHER MANNER
PROVIDED BY LAW. NOTHING IN THE AGREEMENT SHALL AFFECT ANY RIGHT THAT AGENT AND
PURCHASERS MAY OTHERWISE HAVE TO BRING ANY ACTION OR PROCEEDING RELATING TO THIS
AGREEMENT, THE NOTES OR ANY OTHER TRANSACTION DOCUMENT AGAINST THE COMPANY OR
ITS PROPERTIES IN THE COURTS OF ANY JURISDICTION.

          (b) THE COMPANY HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES, TO THE
FULLEST EXTENT IT MAY LEGALLY AND EFFECTIVELY DO SO, ANY OBJECTION THAT IT MAY
NOW OR HEREAFTER HAVE TO THE LAYING OF VENUE OF ANY SUIT, ACTION OR PROCEEDING
ARISING OUT OF OR RELATING TO THIS AGREEMENT, THE NOTES OR ANY OTHER TRANSACTION
DOCUMENT IN ANY DELAWARE OR FEDERAL COURT. EACH OF THE PARTIES HERETO HEREBY
IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, THE DEFENSE OF AN
INCONVENIENT FORUM TO THE MAINTENANCE OF SUCH ACTION OR PROCEEDING IN ANY SUCH
COURT.

          (c) EACH PARTY TO THIS AGREEMENT IRREVOCABLY CONSENTS TO SERVICE OF
PROCESS IN THE MANNER PROVIDED FOR NOTICES IN SECTION 10.6 HEREOF. NOTHING IN
THIS AGREEMENT SHALL AFFECT THE RIGHT OF ANY PARTY TO THIS AGREEMENT TO SERVICE
PROCESS IN ANY OTHER MANNER PERMITTED BY LAW.

                                       18
<PAGE>
     10.10 JURY TRIAL WAIVER. THE COMPANY HEREBY IRREVOCABLY WAIVES ANY RIGHT TO
TRIAL BY JURY IN ANY ACTION OR PROCEEDING (I) TO ENFORCE OR DEFEND ANY RIGHTS
UNDER OR IN CONNECTION WITH THIS AGREEMENT, OR (II) ARISING FROM ANY DISPUTE OR
CONTROVERSY IN CONNECTION WITH OR RELATED TO THIS AGREEMENT AND AGREE THAT ANY
SUCH ACTION OR COUNTERCLAIM SHALL BE TRIED BEFORE A COURT AND NOT BEFORE A JURY.

     10.11 SEVERABILITY. Whenever possible, each provision of this Agreement
shall be interpreted in such manner as to be effective and valid under
applicable Law, but if any provision of this Agreement is held to be prohibited
by or invalid under applicable Law in any jurisdiction, such provision shall be
ineffective only to the extent of such prohibition or invalidity, without
invalidating any other provision of this Agreement.

     10.12 HEADINGS. Article, section and subsection headings and the table of
contents in this Agreement are included for convenience of reference only and
shall not constitute a part of this Agreement for any other purpose.

     10.13 INDEMNITY. The Company hereby agrees to indemnify, defend and hold
harmless the Purchasers and their officers, directors, employees, agents and
representatives, and their respective successors and permitted assigns in
connection with any losses, claims, damages, liabilities and expenses, including
reasonable attorneys' fees, to which any Purchaser may become subject (other
than as a result of the gross negligence or willful misconduct of any such
Person), insofar as such losses, claims, damages or liabilities (or actions in
respect thereof) arise out of or by reason of any investigation, litigation or
other proceedings related to or resulting from any act of, or omission by, the
Company or its Affiliates or any officer, director, employee, agent or
representative of the Company or its Affiliates with respect to the
Transactions, the Notes, the Warrants, or any agreements entered into in
connection with any such agreements, instruments or documents and to reimburse
the Purchasers and each such Person and Affiliate, upon demand, for any legal or
other reasonable expenses incurred in connection with investigating or defending
any such loss, claim, damage, liability, expense or action. To the extent that
the foregoing undertakings may be unenforceable for any reason, the Company
agrees to make the maximum contribution to the payment and satisfaction of
indemnified liabilities set forth in this Section 10.13 that is permissible
under applicable law. The indemnified parties hereunder shall give prompt notice
of any claim for which an indemnity or contribution hereunder is sought, and the
failure to give any such notice shall not relieve the Company of its obligations
hereunder, unless such failure shall prejudice any defense that would have
otherwise been available to the Company in respect of such claim.

     10.14 COUNTERPARTS. This Agreement may be executed in any number of
counterparts and by either party hereto on separate counterparts, each of which,
when so executed and delivered, shall be an original, but all such counterparts
shall together constitute one and the same instrument.

     10.15 INTEGRATION. This Agreement and the other Transaction Documents set
forth the entire understanding of the parties hereto with respect to all matters
contemplated hereby and supersede all previous agreements and understandings
among them concerning such matters, including any term sheets. No statements or
agreements, oral or written, made prior to or at the signing hereof, shall vary,
waive or modify the written terms hereof.

                                       19
<PAGE>
                                SIGNATURE PAGE TO
                             NOTE PURCHASE AGREEMENT

     IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of
the day and year first above written.

                                        EPICEPT CORPORATION

                                        By: /s/ John V. Talley
                                            ------------------------------------
                                        Name: John V. Talley
                                        Title: Chief Executive Officer
<PAGE>
                                SIGNATURE PAGE TO
                             NOTE PURCHASE AGREEMENT

     IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of
the day and year first above written.

                                        TVM IV GMBH & CO. KG

                                        By: /s/ John J. DiBello
                                            ------------------------------------
                                        Name: John J. DiBello
                                        Title: Managing Limited Partner

                                        By: /s/ Mark Cipriano
                                            ------------------------------------
                                        Name: Mark Cipriano
                                        Title: Authorized Signatory
<PAGE>
                                SIGNATURE PAGE TO
                             NOTE PURCHASE AGREEMENT

     IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of
the day and year first above written.

                                        PRIVATE EQUITY DIRECT FINANCE

                                        By: /s/ Rick Gorter and Gwen McLaughlin
                                            ------------------------------------
                                        Name: Rick Gorter and Gwen McLaughlin
                                        Title: Directors
<PAGE>
                                SIGNATURE PAGE TO
                             NOTE PURCHASE AGREEMENT

     IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of
the day and year first above written.

                                        THE MERLIN BIOSCIENCES FUND L.P.

                                        By: Merlin General Partner II Limited,
                                            its General Partner

                                        By: /s/ Denzil Boschat
                                            ------------------------------------
                                        Name: Denzil Boschat
                                        Title: Director

                                        THE MERLIN BIOSCIENCES FUND GBR

                                        By: Merlin General Partner II Limited,
                                            its Managing General Partner

                                        By: /s/ Denzil Boschat
                                            ------------------------------------
                                        Name: Denzil Boschat
                                        Title: Director
<PAGE>
                                SIGNATURE PAGE TO
                             NOTE PURCHASE AGREEMENT

     IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of
the day and year first above written.

                                        SANDERS OPPORTUNITY FUND, L.P.

                                        By: SOF Management, LLC

                                        By: /s/ Don A. Sanders
                                            ------------------------------------
                                        Name: Don A. Sanders
                                        Title: Manager

                                        SANDERS OPPORTUNITY FUND
                                        (INSTITUTIONAL), L.P.

                                        By: SOF Management, LLC

                                        By: /s/ Don A. Sanders
                                            ------------------------------------
                                        Name: Don A. Sanders
                                        Title: Manager
<PAGE>
                                TABLE OF CONTENTS

<TABLE>
<CAPTION>
                                                                            PAGE
                                                                            ----
<S>                                                                         <C>
ARTICLE 1 DEFINITIONS....................................................     1
   1.1     Certain Definitions...........................................     1
   1.2     Accounting Principles.........................................     4
   1.3     Other Definitional Provisions; Construction...................     4

ARTICLE 2 ISSUE AND SALE OF SECURITIES...................................     4
   2.1     Notes.........................................................     4
   2.2     Authorization and Issuance of the Warrants....................     4
   2.3     Sale and Purchase.............................................     4
   2.4     The Closing...................................................     4
   2.5     Delivery of the Certificates Representing the Notes and the
           Warrants to Regulation S Purchasers...........................     5

ARTICLE 3 REPAYMENT OF NOTES.............................................     6
   3.1     Interest Rates................................................     6
   3.2     Repayment of Notes............................................     6
   3.3     Optional Prepayment of Notes..................................     6
   3.4     Mandatory Prepayment..........................................     6

ARTICLE 4 CONDITIONS.....................................................     7
   4.1     Conditions to the Purchase of Securities......................     7
   4.2     Waiver........................................................     8

ARTICLE 5 REPRESENTATIONS AND WARRANTIES OF THE LOAN PARTIES.............     8
   5.1     Representations and Warranties of the Company.................     8

ARTICLE 6 REPRESENTATIONS AND WARRANTIES BY THE PURCHASERS...............    10
   6.1     Representations and Warranties of the Purchasers..............    10
   6.2     Additional Representations and Warranties of the Regulation S
           Purchasers....................................................    11

ARTICLE 7 TRANSFER OF SECURITIES.........................................    11
   7.1     Restricted Securities.........................................    12
   7.2     Legends.......................................................    12
   7.3     Transfer of Notes.............................................    12
</TABLE>

                                        i
<PAGE>
                                TABLE OF CONTENTS
                                   (CONTINUED)

<TABLE>
<CAPTION>
                                                                            PAGE
                                                                            ----
<S>                                                                         <C>
   7.4     Replacement of Lost Securities................................    13
   7.5     No Other Representations Affected.............................    13

ARTICLE 8 COVENANTS......................................................    13
   8.1     Limitation on Indebtedness....................................    13

ARTICLE 9 EVENTS OF DEFAULT..............................................    14
   9.1     Events of Default.............................................    14
   9.2     Consequences of Event of Default..............................    15

ARTICLE 10 MISCELLANEOUS.................................................    16
   10.1    Successors and Assigns........................................    16
   10.2    Modifications and Amendments..................................    16
   10.3    No Implied Waivers; Cumulative Remedies; Writing Required.....    16
   10.4    Reimbursement of Expenses.....................................    16
   10.5    Holidays......................................................    16
   10.6    Notices.......................................................    16
   10.7    Survival......................................................    17
   10.8    Governing Law.................................................    17
   10.9    Jurisdiction, Consent to Service of Process...................    17
   10.10   Jury Trial Waiver.............................................    18
   10.11   Severability..................................................    18
   10.12   Headings......................................................    18
   10.13   Indemnity.....................................................    19
   10.14   Counterparts..................................................    19
   10.15   Integration...................................................    19
</TABLE>

                                       ii
<PAGE>
<TABLE>
<S>                        <C>
Annex A                    Information Relating to U.S. Purchasers
Annex B                    Information Relating to QIB Purchasers
Annex C                    Information Relating to Regulation S Purchasers

                                    SCHEDULES

"Capitalization"           (Schedule 5.1(d))
"Permitted Indebtedness"   (Section 8.1(f))

                                    EXHIBITS

EXHIBIT A                  Form of Note
EXHIBIT B                  Form of Warrant
EXHIBIT C                  Form of Waiver of Right of First Refusal
EXHIBIT D                  Form of Amended and Restated Registration Rights
                           Agreement
</TABLE>

                                        i<PAGE>
                                                                   Exhibit 10.19

                                                                  EXECUTION COPY

     NEITHER THIS NOTE NOR THE SECURITIES ISSUABLE PURSUANT HERETO HAVE BEEN
     REGISTERED OR QUALIFIED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR
     APPLICABLE FOREIGN OR STATE SECURITIES LAWS. THIS NOTE AND SUCH SECURITIES
     MAY NOT BE TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS THEY HAVE BEEN SO
     REGISTERED AND QUALIFIED, OR AN OPINION OF COUNSEL SATISFACTORY TO THE
     COMPANY TO THE EFFECT THAT SUCH REGISTRATION AND QUALIFICATION IS NOT
     REQUIRED HAS BEEN DELIVERED TO THE COMPANY.

                  AMENDED AND RESTATED 8% SENIOR NOTE DUE 2006

No. 4                                                            August 26, 2005
$1,000,000.00

     FOR VALUE RECEIVED, EpiCept Corporation, a Delaware corporation (the
"COMPANY"), hereby promises to pay to the order of TVM IV GMBH & CO. KG and its
successors and assigns (the "Holder"), the principal sum of ONE MILLION DOLLARS
($1,000,000.00) (the "PRINCIPAL AMOUNT"), on the terms and conditions set forth
in the Amended and Restated Note Purchase Agreement, dated as of August 26, 2005
(the "PURCHASE AGREEMENT"), among the Company and the Purchasers identified on
Annex A and Annex B thereto (the "PURCHASERS"). Subject to the conversion,
prepayment and default provisions set forth in this Note and the Purchase
Agreement, all outstanding principal and accrued and unpaid interest under this
Note shall become due and payable on October 30, 2006.

     Payments of principal of, interest on and any premium with respect to this
Note are to be made in lawful money of the United States of America by check
mailed and addressed to the registered Holder hereof at the address shown in the
register maintained by the Company for such purpose, or, at the option of the
Holder, in such manner and at such other place in the United States of America
as the Holder hereof shall have designated to the Company in writing.

     Notwithstanding any provision to the contrary in this Note, the Purchase
Agreement or any other agreement, the Company shall not be required to pay, and
the Holder shall not be permitted to contract for, take, reserve, charge or
receive, any compensation which constitutes interest under applicable law in
excess of the maximum amount of interest permitted by law.

     This Note is one of a series of Amended and Restated 8% Senior Notes Due
2006 (herein called the "AMENDED AND RESTATED Notes") issued pursuant to the
Purchase Agreement and the existing 8% Senior Notes Due 2006 (together with the
Amended and Restated Notes, the "NOTES") and is entitled to the benefits
thereof. All capitalized terms used herein but not otherwise defined shall have
the meanings ascribed to them in the Purchase Agreement. Each Holder of this
Note will be deemed, by its acceptance hereof, to have agreed to the provisions
and to have made the representations and warranties set forth in Article 6 of
the Purchase Agreement.
<PAGE>
     This Note is transferable only by surrender hereof in accordance with
Article 7 of the Purchase Agreement, duly endorsed or accompanied by a written
instrument of transfer duly executed by the registered Holder of this Note.

     This Note is also subject to optional prepayment, in whole or in part, at
the times and on the terms specified in the Purchase Agreement.

     This Note is also subject to mandatory prepayment on the terms specified in
the Purchase Agreement.

     Immediately prior to the Effective Time (as defined in the Merger
Agreement) of the Merger, the outstanding principal of and accrued and unpaid
interest on the Amended and Restated Notes shall automatically convert, without
further act on the part of the Holder, into shares of Common Stock at a
conversion price of $0.71.

     If the Company fails to consummate an initial public offering (the "INITIAL
PUBLIC OFFERING") and thereafter consummates a debt or equity financing with
gross proceeds to the Company of at least $15,000,000 (a "QUALIFYING
FINANCING"), then, simultaneously with the closing of such Qualifying Financing,
the outstanding principal and accrued and unpaid interest on this Note shall, at
the Holder's option, be converted into the number of securities determined by
dividing the principal amount, plus accrued and unpaid interest, outstanding at
the conversion date by the purchase or issue price of the securities sold or
issued in the Qualifying Financing. Such conversion shall occur at the lowest
price paid by any purchaser in the Qualifying Financing. To effect such
conversion, the Payee shall on or before the closing of the Qualifying Financing
become a party to all agreements between the Company and the purchasers in the
Qualifying Financing which set forth the terms and conditions of such purchase
and the Payee shall be entitled to all the rights granted to the purchasers
thereunder and subject to any restrictions or obligations imposed generally on
such purchasers. The Company will mail or cause to be mailed to the Payee a
notice specifying the date on which such Qualifying Financing is scheduled to
close. Such notice will be mailed at least twenty (20) days prior to the date of
such closing.

     If an Event of Default as defined in the Purchase Agreement occurs and is
continuing, the unpaid principal and accrued and unpaid interest on this Note
may be declared or otherwise become due and payable in the manner, at the price
(including any applicable premium) and with the effect provided in the Purchase
Agreement.

     Time is of the essence of this Note. To the fullest extent permitted by
applicable law, the Company, for itself and its legal representatives,
successors and assigns, expressly waives presentment, demand, protest, notice of
dishonor, notice of maturity, notice of non-payment, notice of protest,
presentment for the purpose of accelerating maturity, diligence in collection,
and any exemption, each in respect of this Note.

     In no event, whether by reason of acceleration of the maturity of the
amounts due under the Note or otherwise, shall interest and fees contracted for,
charged, received, paid or agreed to be paid to the Holder exceed the maximum
amount permissible under applicable Law. If, from any circumstance whatsoever,
interest and fees would otherwise be payable to the Holder in

                                        2
<PAGE>
excess of the maximum amount permissible under applicable Law, the interest and
fees shall be reduced to the maximum amount permitted under such Law. If from
any circumstance, the Holder shall have received anything of value deemed
interest by applicable Law in excess of the maximum lawful amount, an amount
equal to any excess of interest shall be applied to the reduction of the
principal amount of the Notes, in such manner as may be determined by the
Holder, and not to the payment of fees or interest, or if such excess interest
exceeds the unpaid balance of the principal amount of the Notes, such excess
shall be refunded to the Company.

     Whenever possible, each provision of this Note shall be interpreted in such
manner as to be effective and valid under applicable Law, but if any provision
of this Note is held to be prohibited by or invalid under applicable Law in any
jurisdiction, such provision shall be ineffective only to the extent of such
prohibition or invalidity, without invalidating any other provision of this
Note.

     This Note and the rights and obligations of the parties hereto shall be
deemed to be contracts under the laws of the State of Delaware and for all
purposes shall be governed by and construed and enforced in accordance with the
laws of said State, except for its rules relating to the conflict of laws.

                                      * * *

                                        3
<PAGE>
     IN WITNESS WHEREOF, the Company has caused this Amended and Restated Note
to be executed and delivered by its respective duly authorized officer as of the
day and year and at the place set forth above.

                                        EPICEPT CORPORATION

                                        By: /s/ John V. Talley
                                            ------------------------------------
                                        Name: John V. Talley
                                        Title: Chief Executive Officer

                             SIGNATURE PAGE TO NOTE

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00092-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00092-of-00352.parquet"}]]